Early Post-Clearance Momentum Signals Accelerated Hospital Adoption of Advanced RoboticsHINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company’s recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance ...

Core Insights - The LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET), indicating its growing commercial traction and relevance in the field of endovascular procedures [1][3] Company Overview - Microbot Medical Inc. is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY system being the world's first FDA cleared single-use, remotely operated robotic solution [4] Product Highlights - The LIBERTY Endovascular Robotic System is designed for precision vascular navigation, aiming to reduce radiation exposure and physical strain on clinicians [3] - It is the only FDA cleared, single-use endovascular robotic system, which is expected to drive broader adoption in peripheral endovascular interventions as procedures become more complex [2][3] Market Strategy - The company commenced a limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption [3]

Core Insights - Microbot Medical Inc. is participating in the Society of Interventional Oncology (SIO) annual meeting to share insights and experiences regarding its LIBERTY Endovascular Robotic System, which is currently in a limited market release phase [1][2] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [3][4] - The company aims to accelerate commercial awareness and adoption of the LIBERTY System through direct engagement with interventional oncologists at the conference [1][2] Company Overview - Microbot Medical Inc. focuses on transforming endovascular procedures with advanced robotic technology, highlighted by the LIBERTY Endovascular Robotic System [4] - The company has a strong intellectual property portfolio and is committed to innovation in the medical device sector [4] Market Context - The interventional oncology market is described as a large and expanding multi-billion dollar sector, with increasing procedure volumes driving demand for advanced technologies like LIBERTY [2] - The full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference [3]

Core Insights - Emory University Hospital has become the first hospital to adopt the LIBERTY Endovascular Robotic System, aligning with its commitment to advancing interventional radiology [1][5] - LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [2][6] - Microbot Medical is collaborating with Emory to establish an Endovascular Robotics Program, aiming to improve patient care in various peripheral intervention procedures [1][3] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with LIBERTY being the first FDA-cleared single-use robotic solution [6] - The company emphasizes innovation and has a strong intellectual property portfolio, positioning itself as a leader in the future of endovascular care [6] Market Strategy - The limited market release of LIBERTY has commenced, with plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026 [2] - The adoption of LIBERTY is seen as a significant milestone in the surgical robotic space, reflecting years of dedication and progress by the Microbot team [5]

Core Insights - Stereotaxis (STXS) has launched its Synchrony system in Europe and submitted a 510(k) application to the U.S. FDA, aiming to modernize interventional cath labs with a unified digital interface [1][5] - The Synchrony system enhances workflow, visualization, and connectivity, positioning Stereotaxis to expand its market presence in both robotic and non-robotic cath labs [2][4] Product Features - Synchrony features a 55-inch ultra-high-definition 4K display that integrates multiple system feeds into a single interface, providing near-zero latency video streams and customizable layouts [3] - The system is paired with SynX, a secure cloud-based application that enables remote connectivity, collaboration, and real-time monitoring, compliant with HIPAA and GDPR standards [3][4] Strategic Vision - Synchrony and SynX are foundational platforms designed to support future advancements, including AI-driven automation and long-distance robotic procedures, aligning with Stereotaxis' long-term digital surgery vision [4] - The CE Mark approval allows for commercial rollout in EU markets, while the FDA submission paves the way for potential entry into the U.S. market, enhancing Stereotaxis' geographic reach [5] Competitive Landscape - Stereotaxis competes with key players like Intuitive Surgical (ISRG), which has advanced its da Vinci 5 platform with new software features and gained CE Mark approval for broader international rollout [6][7] - Microbot Medical (MBOT) has achieved FDA clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone in the endovascular robotics market [8][10] - PROCEPT BioRobotics (PRCT) reported strong revenue growth and wider adoption of its Aquablation therapy, indicating a competitive environment in robotic-assisted surgical solutions [11][12]

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]

Core Insights - Microbot Medical Inc. is set to launch its LIBERTY Endovascular Robotic System in Q4 2025, with a broader release planned for April 2026 during a major conference [1][4] Group 1: Company Overview - Microbot Medical Inc. specializes in innovative medical devices, focusing on transforming endovascular procedures through advanced robotic technology [4] - The LIBERTY System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and safety [4] Group 2: Partnership and Logistics - The company has partnered with a U.S.-based third-party logistics (3PL) provider to support the commercialization of the LIBERTY System, ensuring effective inventory management and customer support [1][2] - The 3PL provider specializes in the medical device industry, allowing the company to leverage its proximity to key markets and maintain inventory in a climate-controlled warehouse [2] Group 3: Operational Strategy - The partnership with an established logistics provider is expected to enhance the company's go-to-market initiatives, making the commercial launch of LIBERTY more efficient [3]

Core Viewpoint - Microbot Medical Inc. has successfully closed the first tranche of a preferred investment options offering, raising approximately $25.2 million, with a second tranche expected to yield an additional $4 million, and potential gross proceeds of up to $63 million from future exercises of short-term preferred investment options [1][4]. Group 1: Offering Details - The first closing involved the exercise of preferred investment options to purchase up to 12,064,627 shares of common stock at exercise prices ranging from $1.50 to $2.13 per share [2]. - The second closing is anticipated by October 15, 2025, and will involve the exercise of options for 1,924,488 shares at an exercise price of $2.10 per share, with new options issued at $4.50 per share [2][4]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated towards the development, commercialization, and regulatory activities for the LIBERTY Robotic System, potential acquisitions, and general corporate purposes [4]. Group 3: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [7].

Core Insights - Microbot Medical Inc. (MBOT) has received a new U.S. patent that enhances the LIBERTY Endovascular Robotic System's applications, allowing for interchangeable tool-receiver units, thus broadening its use in endovascular procedures [1][8] - The new intellectual property (IP) is expected to increase the addressable market for the company from approximately 2.5 million to over six million annual endovascular procedures in the U.S., significantly expanding its market potential [2][8] - Following the patent announcement, MBOT's shares rose by 7.1%, with a year-to-date increase of 195.5%, contrasting with a 7% decline in the industry [3][7] Company Developments - The newly granted patent strengthens Microbot's long-term growth prospects by broadening the LIBERTY system's potential applications, enhancing its competitive differentiation and positioning for future partnerships and revenue opportunities once FDA clearance is obtained [4][8] - MBOT currently has a market capitalization of $140.7 million and projects an earnings growth of 56.2% for the current year [5] Product Overview - The LIBERTY system is designed as a single-use, fully disposable robotic platform for endovascular procedures, aimed at simplifying workflow and reducing risks associated with reprocessing [9][10] - Its modular architecture allows for configuration across various clinical applications, potentially increasing its relevance in a wider range of procedures than initially targeted [9][10]

Core Insights - The company has received a new patent for its LIBERTY Endovascular Robotic System, bringing its total to 12 granted patents globally and 57 pending applications, which enhances its intellectual property portfolio [1][2] - The new patent allows for modular capabilities in the robotic system, potentially expanding its application to a wider range of endovascular procedures, thereby increasing the Total Addressable Market (TAM) [1][2] - The company aims to address over 6 million annual endovascular procedures in the U.S., significantly higher than the current estimate of 2.5 million procedures [2][3] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics and improving patient care globally [4] - The company has developed the first single-use, fully disposable endovascular robotic system, which aims to remove traditional barriers to accessing advanced robotic systems [4]